Catecholamine/serotonin interactions. Systems thinking for brain function and disease.

Advances in Pharmacology

Volumn 68, Issue , 2013, Pages 167-197

  Hensler, Julie G ^a   Artigas, Francesc ^b,c   Bortolozzi, Analía ^b,c   Daws, Lynette C ^a,d   De Deurwaerdère, Philippe ^e   Milan, Léa ^e   Navailles, Sylvia ^e   Koek, Wouter ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Depression; L DOPA; Organic cation transporter; Parkinson's disease; Plasma membrane monoamine transporter; Schizophrenia; Serotonin

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 4 AMINOBUTYRIC ACID RECEPTOR; ADOPRAZINE; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BUSPIRONE; CATECHOLAMINE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; F 15599; HALOPERIDOL; LEVODOPA; MIRTAZAPINE; NEUROPROTECTIVE AGENT; OLANZAPINE; PIMAVANSERIN; PROTEIN C FOS; QUETIAPINE; RACLOPRIDE; REBOXETINE; RISPERIDONE; SEROTONIN; TANDOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; BIPOLAR DISORDER; BRAIN DISEASE; BRAIN FUNCTION; COGNITIVE DEFECT; DRUG RECEPTOR BINDING; EXECUTIVE FUNCTION; HUMAN; LEARNING; MAJOR DEPRESSION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SHORT TERM MEMORY; WORKING MEMORY;

DEPRESSION; L-DOPA; ORGANIC CATION TRANSPORTER; PARKINSON'S DISEASE; PLASMA MEMBRANE MONOAMINE TRANSPORTER; SCHIZOPHRENIA; SEROTONIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; DOPAMINE; HUMANS; PARKINSON DISEASE; SCHIZOPHRENIA; SEROTONIN;

EID: 84884320581     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411512-5.00009-9     Document Type: Chapter

References (53)

1. Artigas F. The prefrontal cortex: A target for antipsychotic drugs. Acta Psychiatrica Scandinavica 2010, 121(1):11-21.
2. Aston-Jones G. The locus coeruleus, A5 and A7 noradrenergic cell groups. The rat nervous system 2004, 183-213. Academic Press, Boca Raton. G. Paxinos (Ed.).
3. Bacq A., Balasse L., Biala G., Guiard B., Gardier A.M., Schinkel A., et al. Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Molecular Psychiatry 2012, 17:926-939.
4. Baganz N.L., Horton R.E., Calderon A.S., Owens W.A., Munn J.L., Watts L.T., et al. Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:18976-18981.
5. Baganz N.L., Horton R.E., Martin K., Holmes A., Daws L.C. Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: Organic cation transporter 3, the smoking gun. Journal of Neuroscience 2010, 30:15185-15195.
6. Bishop C., George J.A., Buchta W., Goldenberg A.A., Mohamed M., Dickinson S.O., et al. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. European Journal of Neuroscience 2012, 36:2839-2848.
7. Björkholm C., Jardemark K., Marcus M.M., Malmerfelt A., Nyberg S., Schilström B., et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. European Neuropsychopharmacology 2013, 23:709-720.
8. Björklund A., Lindvall O. Catecholaminergic brain stem regulatory systems. Handbook of physiology. The nervous system. IV. Intrinsic regulatory systems of the brain 1986, 677-700. American Physiological Society, Bethesda, MD, Bethesda, MD: Distributed by the Williams & Wilkins Co., 1986. V.B. Mountcastle, F.E. Bloom, S.R. Geiger (Eds.).
9. 2A receptors enhances dopaminergic activity. Journal of Neurochemistry 2005, 95:1597-1607.
10. Bortolozzi A., Masana M., Díaz-Mataix L., Cortés R., Scorza M.C., Gingrich J.A., et al. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. The International Journal of Neuropsychopharmacology 2010, Nov, 13(10):1299-1314.
11. Bunin M.A., Wightman R.M. Paracrine neurotransmission in the CNS: Involvement of 5-HT. Trends in Neurosciences 1999, 22:377-382.
12. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area: Target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. Journal of Neuroscience 2000, 20:3864-3873.
13. Celada P., Artigas F. Serotonergic modulation of cortical activity. Monoaminergic modulation of cortical excitability 2007, 197-207. Springer, New York, USA. K.Y. Tseng, M. Atzori (Eds.).
14. Cragg S.J., Rice M.E. DAncing past the DAT at a DA synapse. Trends in Neurosciences 2004, 27:270-277.
15. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:8043-8048.
16. Dahlin A., Xia L., Kong W., Hevner R., Wang J. Expression and immunolocalization of the plasma membrane monoamine transporter in brain. Neuroscience 2007, 146:1193-1211.
17. Daws L.C. Unfaithful neurotransmitter transporters: Focus on serotonin uptake and implications for antidepressant efficacy. Pharmacology and Therapeutics 2009, 121:89-99.
18. Daws L.C., Koek W., Mitchell N.C. Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders. ACS Chemical Neuroscience 2013, 4:16-21.
19. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role in atypical antipsychotic action. Journal of Neuroscience 2005, 25:10831-10843.
20. Duan H., Wang J. Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. Journal of Biological Chemistry 2012, 288:3535-3544.
21. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacology and Therapeutics 2001, 91:35-62.
22. Engel K., Wang J. Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Molecular Pharmacology 2005, 68:1397-1407.
23. Engel K., Zhou M., Wang J. Identification and characterization of a novel monoamine transporter in the human brain. Journal of Biological Chemistry 2004, 279:50042-50049.
24. Eskow K., Angoa-Perez M., Kuhn D., Bishop C. Potential mechanism underlying anxiety and depression in Parkinson's disease: Consequences of L-DOPA treatment. Neuroscience and Biobehavioral Reviews 2011, 35:556-564.
25. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Movement Disorders 2008, 23:S497-S508.
26. Feng N., Lowry C.A., Lukkes J.L., Orchinik M., Forster G.L., Renner K.J. Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint. Brain Research 2010, 1326:105-113.
27. Fox M.A., Jensen C.L., Gallagher P.S., Murphy D.L. Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. Neuropharmacology 2007, 53:643-656.
28. Gasser P.J., Chan C., Ebben A., Hill J.E., Robble M., Wheeler D.S., et al. Glucocorticoid-sensitive dopamine clearance in the nucleus accumbens: Organic cation transporter 3 as a mechanism for stress-induced enhancement of dopaminergic neurotransmission 2012, http://meetingassistant5.com/XICS2012/core_routines/view_abstract_no.php?abstractno=105.
29. Goldman-Rakic P.S., Muly E.C., Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Research Reviews 2000, 31:295-301.
30. Horton R.E., Apple D.M., Owens W.A., Baganz N.L., Cano S., Mitchell N.A., et al. Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: Uncovering novel targets to treat depression. Journal of Neuroscience 2013, 33:10534-10543.
31. Jodo E., Chiang C., Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 1998, 83:63-79.
32. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: An effect mediated by ventral tegmental area. Journal of Neurochemistry 1996, 66:589-598.
33. Kitaichi K., Fukuda M., Nakayama H., Aoyama N., Ito Y., Fujimoto Y., et al. Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neuroscience Letters 2005, 382:195-200.
34. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharmaceutical Research 2007, 24:1227-1251.
35. Koepsell H., Schmitt B.M., Gorboulev V. Organic cation transporters. Reviews of Physiology, Biochemistry and Pharmacology 2003, 150:36-90.
36. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: Temporal and quantitative relationship to the expression of dyskinesia. Journal of Neurochemistry 2010, 112:1465-1476.
37. Masana M., Bortolozzi A., Artigas F. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: Therapeutic opportunities in schizophrenia. The International Journal of Neuropsychopharmacology 2011, 14:53-68.
38. Masana M., Santana N., Artigas F., Bortolozzi A. Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: A critical review. Current Topics in Medicinal Chemistry 2012, 12:2357-2374.
39. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
40. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiology of Disease 2010, 38:136-143.
41. Navailles S., Bioulac B., Gross C.De, Deurwaerdère P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiology of Disease 2011, 41:585-590.
42. Navailles S., Carta M., Guthrie M., De Deurwaerdere P. L-DOPA and serotonergic neurons: Functional implication and therapeutic perspectives in Parkinson's disease. Central Nervous System Agents in Medicinal Chemistry 2011, 11:305-320.
43. Navailles S., Lagière M., Contini A., De Deurwaerdère P. Multisite intracerebral microdialysis to study the mechanism of L-DOPA-induced dopamine and serotonin release in the parkinsonian brain. ACS Chemical Neuroscience(ahead of publication) 2013.
44. Rahman Z., Ring R.H., Young K., Platt B., Lin Q., Schechter L.E., et al. Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine. Brain Research 2008, 1203:68-78.
45. Rappold P.M., Cui M., Chesser A.S., Tibbett J., Grima J.C., Duan L., et al. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:20766-20771.
46. Skolnick P., Krieter P., Tizzano J., Basile A., Popik P., Czobor P., et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Reviews 2006, 12:123-134.
47. Stansley B.J., Yamamoto B.K. L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology 2012, 67C:243-251.
48. Steinbush H.W. Serotonin-immunoreactive neurons and their projections in the CNS. Classical transmitters and transmitter receptors in the CNS, Part II Handbook of chemical neuroanatomy 1984, Vol. 3:68-125. Elsevier, Amsterdam. A. Björklund, T. Hökfelt, M.J. Kuhar (Eds.).
49. Stone E.A., Lin Y. An anti-immobility effect of exogenous corticosterone in mice. European Journal of Pharmacology 2008, 580:135-142.
50. Vialou V., Amphoux A., Zwart R., Giros B., Gautron S. Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. Journal of Neuroscience 2004, 24:2846-2851.
51. Vijayraghavan S., Wang M., Birnbaum S.G., Williams G.V., Arnsten A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nature Neuroscience 2007, 10:376-384.
52. Wilkinson L.S. The nature of interactions involving prefrontal and striatal dopamine systems. Journal of Psychopharmacology 1997, 11:143-150.
53. Williams G.V., Castner S.A. Under the curve: Critical issues for elucidating D1 receptor function in working memory. Neuroscience 2006, 139:263-276.